These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24121041)

  • 41. [The relationship and clinicopathological significance of Numb,MDM2 and p53 expression in human pancreatic cancer].
    Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
    Zhonghua Wai Ke Za Zhi; 2014 Sep; 52(9):675-81. PubMed ID: 25410780
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
    Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
    Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Laminin gamma2-chain fragment circulating level increases in patients with metastatic pancreatic ductal cell adenocarcinomas.
    Katayama M; Funakoshi A; Sumii T; Sanzen N; Sekiguchi K
    Cancer Lett; 2005 Jul; 225(1):167-76. PubMed ID: 15922869
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comprehensive examination of Smad4, Smad6 and Smad7 mRNA expression in pancreatic ductal adenocarcinoma.
    Singh P; Wig JD; Srinivasan R; Radotra BD
    Indian J Cancer; 2011; 48(2):170-4. PubMed ID: 21768661
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN.
    Yamaguchi K; Kanemitsu S; Hatori T; Maguchi H; Shimizu Y; Tada M; Nakagohri T; Hanada K; Osanai M; Noda Y; Nakaizumi A; Furukawa T; Ban S; Nobukawa B; Kato Y; Tanaka M
    Pancreas; 2011 May; 40(4):571-80. PubMed ID: 21499212
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detectable expression of IL-35 in CD4+ T cells from peripheral blood of chronic hepatitis B patients.
    Liu F; Tong F; He Y; Liu H
    Clin Immunol; 2011 Apr; 139(1):1-5. PubMed ID: 21285006
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern.
    Kim HW; Lee JC; Paik KH; Kang J; Kim J; Hwang JH
    Medicine (Baltimore); 2017 Feb; 96(5):e5926. PubMed ID: 28151872
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer.
    Ramsey ML; Talbert E; Ahn D; Bekaii-Saab T; Badi N; Bloomston PM; Conwell DL; Cruz-Monserrate Z; Dillhoff M; Farren MR; Hinton A; Krishna SG; Lesinski GB; Mace T; Manilchuk A; Noonan A; Pawlik TM; Rajasekera PV; Schmidt C; Guttridge D; Hart PA
    Pancreatology; 2019 Jan; 19(1):80-87. PubMed ID: 30497874
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pancreatic cancer-associated inflammation drives dynamic regulation of p35 and Ebi3.
    Michaud D; Mirlekar B; Bischoff S; Cowley DO; Vignali DAA; Pylayeva-Gupta Y
    Cytokine; 2020 Jan; 125():154817. PubMed ID: 31472403
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The clinical significance of circulating tumor cells and T lymphocyte subtypes in pancreatic cancer patients.
    Xing Y; Zhang X; Qin F; Yang J; Ai L; Wang Q; Zhai Y
    Bioengineered; 2022 Feb; 13(2):2130-2138. PubMed ID: 35034581
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protein biomarker for pancreatic ductal adenocarcinoma.
    Burki T
    Lancet Oncol; 2017 Sep; 18(9):e511. PubMed ID: 28736187
    [No Abstract]   [Full Text] [Related]  

  • 52. A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer.
    Keane MG; Horsfall L; Rait G; Pereira SP
    BMJ Open; 2014 Nov; 4(11):e005720. PubMed ID: 25410605
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Validation of IL-7R as an Immunological Biomarker for Human Pancreatic Ductal Adenocarcinoma.
    Jang SI; Cho JH; Kim SY; Hong IY; Park JS; Lee HS; Park G; Kim JK; Lee HK; Lee DK
    Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159120
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis.
    Talar-Wojnarowska R; Gasiorowska A; Smolarz B; Romanowicz-Makowska H; Kulig A; Malecka-Panas E
    Dig Dis Sci; 2009 Mar; 54(3):683-9. PubMed ID: 18661238
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Expression of Tregs and IL-35 in Peripheral Blood of Patients with Newly Diagnosed Acute Myeloid Leukemia].
    Yang PX; Wang P; Fang L; Wang Q
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1688-1692. PubMed ID: 36476890
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Personalized mRNA Vaccine Immunogenic against PDAC.
    Cancer Discov; 2023 Jul; 13(7):1504. PubMed ID: 37163684
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pancreatic Ductal Adenocarcinoma: A New TNM Staging System Is Needed!
    Strobel O; Büchler MW
    Ann Surg; 2017 Dec; 266(6):e109-e110. PubMed ID: 27455152
    [No Abstract]   [Full Text] [Related]  

  • 58. Pancreatic Ductal Adenocarcinoma: A New TNM Staging System is Needed!
    Crippa S; Partelli S; Falconi M
    Ann Surg; 2017 Dec; 266(6):e108-e109. PubMed ID: 27455151
    [No Abstract]   [Full Text] [Related]  

  • 59. Plasma Levels of Interleukin-35 and its Association with Clinical Features of Breast Cancer Patients at Assiut University Hospitals.
    El-Gendy SG; El-Sabaa EM; El-Feky MA; Ahmed SH; Eid SS
    Egypt J Immunol; 2019 Jan; 26(1):121-128. PubMed ID: 31333002
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pancreatic cancer: Early events in pancreatic cancer.
    Leake I
    Nat Rev Gastroenterol Hepatol; 2014 Dec; 11(12):703. PubMed ID: 25311477
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.